These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19476859)

  • 1. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
    Olson JA; Budd GT; Carey LA; Harris LA; Esserman LJ; Fleming GF; Marcom PK; Leight GS; Giuntoli T; Commean P; Bae K; Luo J; Ellis MJ
    J Am Coll Surg; 2009 May; 208(5):906-14; discussion 915-6. PubMed ID: 19476859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
    Krainick-Strobel UE; Lichtenegger W; Wallwiener D; Tulusan AH; Jänicke F; Bastert G; Kiesel L; Wackwitz B; Paepke S
    BMC Cancer; 2008 Feb; 8():62. PubMed ID: 18302747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
    Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E
    Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery.
    Carpenter R; Doughty JC; Cordiner C; Moss N; Gandhi A; Wilson C; Andrews C; Ellis G; Gui G; Skene AI
    Breast Cancer Res Treat; 2014 Apr; 144(3):569-76. PubMed ID: 24562823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
    Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
    Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the effect of neoadjuvant chemotherapy on surgical outcomes after breast conserving surgery.
    Woeste MR; Bhutiani N; Donaldson M; McMasters KM; Ajkay N
    J Surg Oncol; 2021 Feb; 123(2):439-445. PubMed ID: 33259649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letrozole in the neoadjuvant setting: the P024 trial.
    Ellis MJ; Ma C
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):33-43. PubMed ID: 17912634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
    Barbie TU; Ma C; Margenthaler JA
    Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of re-excision among women undergoing breast-conserving surgery for cancer.
    Waljee JF; Hu ES; Newman LA; Alderman AK
    Ann Surg Oncol; 2008 May; 15(5):1297-303. PubMed ID: 18259820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
    Skriver SK; Laenkholm AV; Rasmussen BB; Handler J; Grundtmann B; Tvedskov TF; Christiansen P; Knoop AS; Jensen MB; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):31-37. PubMed ID: 29168427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
    Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
    J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy.
    Mazouni C; Naveau A; Kane A; Dunant A; Garbay JR; Leymarie N; Sarfati B; Delaloge S; Rimareix F
    Breast; 2013 Dec; 22(6):1189-93. PubMed ID: 24054903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    Ramalingam K; Clelland E; Rothschild H; Mujir F; Record H; Kaur M; Mukhtar RA
    Ann Surg Oncol; 2023 Nov; 30(12):7099-7106. PubMed ID: 37561345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome.
    van Hemert A; van Loevezijn AA; Bosman A; Vlahu CA; Loo CE; Peeters MTFDV; van Duijnhoven FH; van der Ploeg IMC
    Breast Cancer Res Treat; 2024 Apr; 204(3):497-507. PubMed ID: 38189904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
    Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
    Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative chemotherapy for T2 breast cancer is associated with improved surgical outcome.
    Karanlik H; Ozgur I; Cabioglu N; Sen F; Erturk K; Kilic B; Onder S; Deniz M; Yavuz E; Aydiner A
    Eur J Surg Oncol; 2015 Sep; 41(9):1226-33. PubMed ID: 26141784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer.
    Petrelli F; Barni S
    Breast Cancer Res Treat; 2013 Nov; 142(2):227-35. PubMed ID: 24177758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
    Novoa Vargas A; Font López KC; Amador DD
    Ginecol Obstet Mex; 2011 Sep; 79(9):553-7. PubMed ID: 21966856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.